Results 241 to 250 of about 1,436,444 (347)

Combining TAG‐72CAR with anti‐MUC16CAR improves the potency of ovarian cancer treatment

The FEBS Journal, EarlyView.
Tz‐KBBCAR, a combinatorial CAR targeting MUC16 and TAG‐72, enhances the precision of ovarian cancer immunotherapy. By requiring both tumour antigens for full activation, Tz‐KBBCAR was designed to eliminate MUC16+/TAG‐72+ cancer cells, while sparing MUC16+/TAG‐72‐ healthy cells.
Alicia Villatoro, Aurore Dougé, Klara Krpina, Lea‐Marie Schmitz, Christopher Forcados, Fatemeh Kaveh, Andrea Estrella Arias‐Díaz, Pascal Gelebart, Emmet McCormack, Renata Stripecke, Miguel Abal, Ben Davidson, Else Marit Inderberg, Sébastien Wälchli   +13 more
wiley   +1 more source

CAR T cells against the B cell receptor to precisely eliminate pathogenic B cells. [PDF]

Mol Ther Oncol
Bochi-Layec AC, Cohen IJ, Lemoine J, Ruella M.   +3 more
europepmc   +1 more source

Independent validation of the International Metabolic Prognostic Index (CAR‐IMPI) in patients with aggressive diffuse large B‐cell lymphoma treated with CAR‐T

British Journal of Haematology, EarlyView.
Eugenio Galli, Andrea Guarneri, Alessandro Corrente, Francesca Maria Portonera, Elena Romano Gargarella, Ilaria Pansini, Patrizia Chiusolo, Federica Sorà, Maria Lucia Calcagni, Simona Sica, Stefan Hohaus, Lucia Leccisotti   +11 more
wiley   +1 more source

A guide to studying tumour‐T‐cell interactions using in vitro coculture assays

The FEBS Journal, EarlyView.
In vitro tumour‐T‐cell coculture systems provide a controlled way to study how T cells recognise and kill tumour cells. Different tumour models can be combined with antigen‐specific TCR or CAR T cells, while antigen presentation, cytokines, drugs and tumour genetics can be manipulated.
Nooshin Khoshdoozmasouleh, Conor J. Kearney   +1 more
wiley   +1 more source

B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression. [PDF]

Mol Biomed
Zhang Z, Yang N, Zeng H, Chen Y, Lu H, Xu L, Wang Z, Wang G, Zhou L, Tong A.   +9 more
europepmc   +1 more source

Outcomes for post‐transplant relapsed acute lymphoblastic leukaemia in the era of novel therapies: A retrospective multicentre UK study

British Journal of Haematology, EarlyView.
Alexandros Rampotas, Amy A. Kirkwood, Maximillian Brodermann, Nicola Maciocia, Fotios Panitsas, Sridhar Chaganti, Styliani Bouziana, Emma Nicholson, Samantha Drummond, Michelle Lannon, Amy Publicover, Sharon Allen, Isaac Gannon, Andrew J. King, Anne‐Louise Latif, Henry Crosland, Claire Roddie   +16 more
wiley   +1 more source

Merkel cell carcinoma: an updated guide for pathologists

Histopathology, EarlyView.
Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma for which the differential diagnosis can include other small cell malignancies (especially metastatic small cell carcinoma) or cutaneous carcinoma. Morphologic and immunophenotypic aberrancies in MCC can increase diagnostic challenge.
Paul W. Harms
wiley   +1 more source

Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy. [PDF]

Exp Hematol Oncol
Riet T, Lennartz S, Bösing N, Prinz LF, Dähn L, Scheid C, Hallek M, Chmielewski MM.   +7 more
europepmc   +1 more source

Comparison of intestinal histopathological changes following teclistamab, BCMA‐directed CAR T, CD19‐directed CAR T and rituximab therapies

Histopathology, EarlyView.
This is a retrospective review of intestinal tract biopsies from patients treated with various cellular immunotherapies (BCMA and CD19‐directed CAR T, teclistamab and rituximab therapies). We found distinct but overlapping histologic patterns across treatment groups, with lamina propria plasma cell depletion, crypt apoptotic bodies and active ...
Olivia J Leung, Esther Baranov, Isairis Peralta Valerio, Robin Collingwood, Natalie Respond, Don Siegel, Pooja Devi, Kristen M. Stashek   +7 more
wiley   +1 more source

Progress and promise of CAR-T cell treatment in autoimmune diseases. [PDF]

PLoS Med
Bachl J, Hagen M, Schett G.
europepmc   +1 more source